Orbimed Advisors
Orbimed Advisors reported 113 stocks worth $5.4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (11.6%), ADRX (8.9%) and ELVN (5.7%). Compared with Q2 2026, the fund opened new positions in ADRX, BRVE and ETRA, added to MRK, ARQT and TMO, trimmed MBX, NTRA and ARGX and sold out of DYN, CGON and BSX.
Latest filing: what Orbimed Advisors did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() EWTX Edgewise Therapeutics Inc | $630M | 11.6% | 15.5M | No change | 8 of 8 | |
| 2 | ![]() ADRX Adarx Pharmaceuticals Inc | $483M | 8.9% | 24.2M | New position | 1 of 8 | |
| 3 | ![]() ELVN Enliven Therapeutics Inc | $311M | 5.7% | 6.8M | No change | 8 of 8 | |
| 4 | ![]() LLY Eli Lilly & Co | $298M | 5.5% | 258K | No change | 8 of 8 | |
| 5 | ![]() BRVE Braveheart Bio Inc | $246M | 4.5% | 12.2M | New position | 1 of 8 | |
| 6 | ![]() SVA Sinovac Biotech Ltd | $196M | 3.6% | 2.7M | No change | 8 of 8 | |
| 7 | ![]() MBX Mbx Biosciences Inc | $180M | 3.3% | 3.1M | −354K (−10%) | 8 of 8 | |
| 8 | ![]() MRK Merck & Co Inc | $137M | 2.5% | 946K | +283K (+43%) | 4 of 8 | |
| 9 | ![]() GH Guardant Health Inc | $104M | 1.9% | 584K | No change | 3 of 8 | |
| 10 | ![]() AVBP Arrivent Biopharma Inc | $91.7M | 1.7% | 3M | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() DYN Dyne Therapeutics Inc | $71.9M | 3.2M |
![]() CGON CG Oncology Inc | $69.1M | 973K |
![]() BSX Boston Scientific Corp | $63.3M | 1.5M |
![]() XENE Xenon Pharmaceuticals Inc | $53.9M | 892K |
![]() BMY Bristol Myers Squibb Co | $53.3M | 925K |
🔒 Free account: see all 30.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() PTGX Protagonist Therapeutics Inc | Call | $21.1M | 150K | 0 |
![]() ABVX Abivax SA | Call | $9.9M | 100K | −100,000 |
![]() RVMD Revolution Medicines Inc | Call | $6.2M | 30K | −20,000 |
![]() TNGX Tango Therapeutics Inc | Call | $3.7M | 150K | +150,000 |
![]() BCRX Biocryst Pharmaceuticals Inc | Call | $2.1M | 250K | +250,000 |
🔒 Free account: see all 8.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Orbimed Advisors 13F FAQ
What does Orbimed Advisors own?
Orbimed Advisors reported 113 stocks worth $5.4B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are EWTX (11.6%), ADRX (8.9%) and ELVN (5.7%). The table above lists every position in the filing (the top 10 without an account).
What did Orbimed Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 29 new positions, 16 added to, 34 trimmed and 32 sold out. New positions include ADRX, BRVE and ETRA. It sold all of DYN, CGON and BSX.
When will Orbimed Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Orbimed Advisors's portfolio worth?
The Q3 2026 filing reports $5.4B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





























